Search results
Scientists Are Studying Weight-Loss Drugs for Way More Than Weight Loss
Time via AOL· 21 hours agoKidney disease People with diabetes often develop kidney complications. Those taking the drug...
Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset
FierceBiotech· 2 hours agoBoehringer Ingelheim is handing over a total of 38.8 million euros ($42 million) to long-time partner OSE Immunotherapeutics for a preclinical anti-PD1/cytokine drug as well ...
Lung cancer risks remain high for smokers who switch to vaping
UPI· 18 hours agoFolks who'd quit smoking for five years or more but were vaping still faced higher odds for fatal...
Olivia Munn documented cancer journey for son to show him 'I tried my best' if she 'didn't make it'
Fox News· 3 days agoOlivia Munn opened up about why she decided to document her cancer journey. Munn said that she...
Weight Loss Drug Can Sustain Results For Up To 4 Years And May Protect Hearts Too
IFLScience· 5 days agoWegovy, an injectable prescription weight loss drug, can produce effective results that help patients keep weight off for up to four years, a new study suggests. The
What's the Difference Between Vegetarian and Pescatarian Diets?
Health via Yahoo News· 18 hours agoFoods are simply seasoned, and small amounts of lean meats, chicken, and eggs are also included....
Signs of Alzheimer’s were everywhere. Then his brain improved | CNN
CNN.com· 4 days agoSanjay Gupta is a practicing neurosurgeon and best-selling author on brain health. Preventive...
What Causes Blood Clots in Lungs (Pulmonary Embolism)?
Health via Yahoo News· 5 days agoMedical History Some conditions are associated with a higher risk of developing deep vein thrombosis...
What Will The Global Disease Landscape Look Like In 2050?
IFLScience· 2 days agoThe GBD study is the most comprehensive effort to quantify health loss around the globe over time....
AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Dive via Yahoo Finance· 23 hours agoTwo trial readouts for new cardiovascular drugs are coming in 2025, while an antibody-drug conjugate called datopotamab deruxtecan is in late-stage...